Brief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
20/05/2026 12:07
May 20 (Reuters) - Skye Bioscience Inc SKYE.O: SKYE ANNOUNCES COHORT REVIEW COMMITTEE APPROVED OPENING OF COHORT 2 BASED ON FAVORABLE SAFETY DATA FROM FIRST FOUR PARTICIPANTS TREATED IN COHORT 1 SKYE BIOSCIENCE INC - CRC APPROVES ENROLLMENT IN COHORT 2 (600 MG IV) AFTER FAVORABLE SAFETY REVIEW OF COHORT 1 Source text: ID:nGNX4v4YTY Further company coverage: SKYE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug